- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02250599
Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma
Multi-center, Randomized, Controlled, Open-label Study of Bevacizumab With Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel in Patients With Metastatic Nasopharyngeal Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nasopharyngeal carcinoma is vastly more common in East Asia, especially China has a high incidence of it, and the number of new cases will account for more than 40% of the world total . The disease involved population maybe more than 4 million in the world. More than 2700-3000 new nasopharyngeal carcinoma patients will be diagnosed in SUN YAT-SEN university cancer center every year. It is most common in 40-50 years old adults and has been a top ten (10th) malignant tumor in Chinese male which threaten human health and social economy.
Chemotherapy is the standard treatment of the advanced nasopharyngeal carcinoma.Several other phase II study also confirmed the effectiveness of paclitaxel and carboplatin (TC) regimen in advanced NPC, so it maybe a simple right choice.
Increasing expression of VEGF in serum associated with poor prognosis in metastatic nasopharyngeal carcinoma. Agents that selectively target VEGF-A and its receptors have shown significant antitumor effects in xenograft models of nasopharyngeal. Studies demonstrated that bevacizumab(AVASTIN) administration with chemotherapy or chemoradiation is feasible in patients with nasopharyngeal cancer. Bevacizumab can be safely combined with a range of cytotoxic and other anticancer agents including TC regimen.
Evidence indicated a potential possibility that the TC+AVASTIN regimen may be superior than TC regimen.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Guangdong
-
Dongguan, Guangdong, China
- Recruiting
- Dongguan People's Hospital
-
Contact:
- Xuefang Zhang
- Email: 674854955@qq.com
-
Principal Investigator:
- Chun Zhang
-
Guangzhou, Guangdong, China
- Recruiting
- First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
-
Principal Investigator:
- Lizhu Lin
-
Contact:
- Xuewu Huang
- Email: doctorhxw@sina.com
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Department of Medical Oncology,Cancer Center of Sun Yat-Sen University
-
Contact:
- li zhang, MD
- Phone Number: 86-20-87343368
- Email: zhangli@sysucc.org.cn
-
Contact:
- Tao Qin
- Phone Number: 13570396232
- Email: tantao@sysucc.org.cn
-
Sub-Investigator:
- Yan Huang, MD
-
Guangzhou, Guangdong, China
- Recruiting
- Guangzhou University of Chinese Medicine
-
Contact:
- Xuewu Huang, M.D.
- Email: doctorhxw@sina.com
-
Principal Investigator:
- Lizhu Lin, M.D.
-
Jiangmen, Guangdong, China
- Recruiting
- JiangMen Central Hospital
-
Contact:
- Yu Wang
- Email: 39672979@qq.com
-
Principal Investigator:
- Xiaofan Ding
-
Shenzhen, Guangdong, China
- Recruiting
- ShenZhen People's Hospital
-
Contact:
- Ruilian Xu
- Email: xuruilian@126.com
-
-
Guangxi
-
Nanning, Guangxi, China
- Recruiting
- The People's Hospital of Guangxi Zhuang Autonomous Region
-
Contact:
- Zhiyong Xu
- Email: 18978187401@189.cn
-
Principal Investigator:
- Guosheng Feng
-
-
Hainan
-
Haikou, Hainan, China
- Recruiting
- Hainan General Hospital
-
Contact:
- Yanju Chen
- Email: cyj-0001@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must meet the following criteria for study entry:
- Age ≥ 18
- Eastern Cooperative Oncology Group (ECOG) performance status 0~1
- Patients with a life expectancy>12 weeks
- Histologically proven NPC diagnosis
- Metastatic nasopharyngeal carcinoma with evidence of unsuitable for local treatment(in terms of some relevant therapy for anti-tumor like surgery, radiofrequency ablation, transcatheter arterial chemoembolization(TACE) and radiotherapy(except palliative radiotherapy for metastatic bone pain with appropriate radiation dosage without influence to the hemogram),etc.)
Neoadjuvant or concurrent chemoradiotherapy was allowed, provided that the treatment was completed at least 3 months before the start of study drug treatment
-≥1 measurable target based on RECIST criteria
- Adequate bone marrow, hepatic and renal function, defined as follows within 1 weeks prior to randomization
- Patients must sign study specific informed consent prior to registration
- Patient must have recovered (be >28 days post-surgery) from the effects of surgery, postoperative infection, and other complications before initial treatment with bevacizumab
- Systolic blood pressure ≤ 160 mmHg and diastolic pressure ≤ 90 mmHg within 7 days prior to randomization.
Exclusion Criteria:
- Prior systemic treatment for metastatic nasopharyngeal carcinoma
- Preparing for receiving local treatment for metastatic nasopharyngeal carcinoma (excluding palliative irradiation to release skeletal pain)
- Prior treatment with bevacizumab or other agents specifically targeting VEGF
- Patients with hemorrhage tendency including acute hemorrhage of digestive tract, nasal bleeding (not including nasal epistaxis), continuous hemorrhagic disease or Coagulation function disorder disease. Patients are using known NSAIDS to inhibit platelets.
- Patients with gross hemoptysis or hematemesis (defined as bright red blood of 1 teaspoon or more or frank clots within minimal or no phlegm per coughing episode) within 4 weeks prior to registration; patients with incidental blood mixed with phlegm are not excluded
- Patients receiving other experimental therapeutic cancer treatment
Severe, active co-morbidity, defined as follows:
i.--Unstable angina and/or congestive heart failure or vascular (e.g. aortic aneurysm requiring surgical repair or peripheral thrombosis) disease requiring hospitalization within the last 12 months, or other cardiac compromise (e.g. an inadequately controlled cardiac arrhythmia) that in the judgment of the investigator will preclude the safe administration of a study drug; Patient must not show sign of recent myocardial infarction or ischemia by the findings of S-T elevations of ≥ 2mm on an EKG ii.--History of arterial thromboembolic events, venous thromboembolism >NCI CTCAE Grade 3, transient ischemic attack (TIA), cerebral vascular accident (CVA), transmural myocardial infarction (MI), or hypertensive crisis or hypertensive encephalopathy iii.--History of ongoing bleeding diathesis, hemorrhagic disorder, or coagulopathy iv.--Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration v.--History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or active GI bleeding within the last 6 months prior to registration; vi.--Esophageal varices, non-healing ulcer, non-healing wound, or bone fracture within the last 6 months prior to registration vii.--Active, untreated infection and/or acute bacterial or fungal infection uiring intravenous antibiotics at the time of registration viii.--Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; ix. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects x. - Minor surgical procedure including placement of a vascular access device, within 2 days of the first study treatment
- Patients currently (within 10 days of study enrollment) taking warfarin, heparin, daily treatment with aspirin (> 325 mg/day), or nonsteroidal anti-inflammatory medications known to inhibit platelet function; treatment with dipyramidole, ticlopidine, clopidogrel, or cilostazol
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception;
- Prior allergic reaction to the study drug(s) involved in this protocol
- Contraindication to Bevacizumab
- Patients has another cancer history (not NPC)within 5 years before randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: carboplatin and paclitaxel
carboplatin and paclitaxel :paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
|
Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle
Carboplatin AUC 6 IV Day 1 each 3-week cycle
|
Experimental: AVASTIN and carboplatin and paclitaxel
AVASTIN and carboplatin and paclitaxel: Bevacizumab(AVASTIN) 7.5 mg/kg intravenously (IV) infusion on Day 1 of each 3-week cycle; paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
|
Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle
Carboplatin AUC 6 IV Day 1 each 3-week cycle
Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression free survival(PFS)
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival(OS)
Time Frame: 3 years
|
3 years
|
|
Number of Participants with Adverse Events
Time Frame: 3 years
|
3 years
|
|
Health-related quality of life
Time Frame: 3 years
|
3 years
|
|
Overall response rate (ORR,CR+PR)
Time Frame: 3 years
|
Identified by investigators and independent radiologic review (IRC) respectively
|
3 years
|
Disease control rate(DCR,CR+PR+SD)
Time Frame: 3 years
|
Identified by investigators and IRC respectively
|
3 years
|
Progression free survival(PFS)
Time Frame: 3 years
|
Identified by IRC
|
3 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Carcinoma
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Carboplatin
- Paclitaxel
- Bevacizumab
Other Study ID Numbers
- ML29153
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasopharyngeal Neoplasms
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Metastatic Nasopharyngeal Nonkeratinizing Carcinoma | Metastatic Nasopharyngeal Undifferentiated Carcinoma | Nasopharyngeal... and other conditionsUnited States, Canada, China, Singapore
-
Cancer Institute and Hospital, Chinese Academy...RecruitingMetastatic Nasopharyngeal CancerChina
-
National Cancer Institute (NCI)CompletedRecurrent Nasopharynx Carcinoma | Stage III Nasopharyngeal Carcinoma AJCC v7 | Stage IV Nasopharyngeal Carcinoma AJCC v7 | Stage IVA Nasopharyngeal Carcinoma AJCC v7 | Stage IVB Nasopharyngeal Carcinoma AJCC v7 | Stage IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal Nonkeratinizing CarcinomaUnited States, Singapore, China
-
National Cancer Centre, SingaporeNovartis; Advanced Accelerator ApplicationsRecruitingMetastatic Nasopharyngeal CancerSingapore
-
Groupe Oncologie Radiotherapie Tete et CouTerminatedNasopharyngeal CancersFrance, Tunisia, Morocco, Romania
-
Alliance for Clinical Trials in OncologyNot yet recruitingRecurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMetastatic Nasopharyngeal CancerChina
-
Royal Marsden NHS Foundation TrustCompletedNasopharyngeal Cancers | Intensity Modulated Radiotherapy With ChemotherapyUnited Kingdom
-
National Cancer Institute (NCI)Not yet recruitingStage IV Nasopharyngeal Carcinoma AJCC v8 | Stage II Nasopharyngeal Carcinoma AJCC v8 | Stage III Nasopharyngeal Carcinoma AJCC v8
-
National Cancer Institute (NCI)CompletedRecurrent Nasopharyngeal Cancer | Stage IV Nasopharyngeal CancerUnited States
Clinical Trials on Paclitaxel
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActive, not recruitingAdvanced Gastric CancerChina
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationCompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
Shengjing HospitalRecruiting
-
CTI BioPharmaTerminatedNSCLCUnited States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
CTI BioPharmaTerminated
-
Novartis PharmaceuticalsCompletedMetastatic or Locally Advanced Solid TumorsNetherlands, Spain, Germany, Switzerland, Belgium